PD-1/PD-l1 inhibitors increase pathological complete response in locally advanced gastric cancer: a meta-analysis and trial sequential analysis
J. gastrointest. cancer (Online); 56 (1), 2025
BACKGROUND AND OBJECTIVE: Gastric cancer (GC) remains a leading cause of morbidity and mortality worldwide. The current standard of care involves neoadjuvant chemotherapy (NACT) followed by radical gastrectomy. This study aims to evaluate the efficacy of neoadjuvant therapy with PD-1/PD-L1 inhibitors in ...